Clinical trial
A Phase III Double-blind Randomised Study Assessing the Efficacy and Safety of Capivasertib/+Paclitaxel vs Placebo+Paclitaxel as First-line Treatment for Patients With Locally Advanced (Inoperable) or Metastatic TNBC.
NCT03997123 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase III Double-blind Randomised Study Assessing the Efficacy and Safety of Capivasertib/+Paclitaxel vs Placebo+Paclitaxel as First-line Treatment for Patients With Locally Advanced (Inoperable) or Metastatic TNBC.
- Lead sponsor
- AstraZeneca
- Phase
- Phase 3
- Overall status
- Active, not recruiting
- Start date
- June 25, 2019
- Completion date
- March 16, 2026
- Enrollment
- 923 (actual)
- Sites
- 260
Conditions
As the registry lists them; a condition with its own page is linked.